Aclaris Therapeutics ACRS Change in fair value of contingent consideration
Change in fair value of contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Aclaris Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's change in fair value of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's change in fair value of contingent consideration?
- Aclaris Therapeutics (ACRS) reported change in fair value of contingent consideration of $400K in Q4 2025.
- What is the long-term trend for Aclaris Therapeutics's change in fair value of contingent consideration?
- Over 3 years (2021 to 2025), Aclaris Therapeutics's change in fair value of contingent consideration has grown at a -54.5% compound annual growth rate (CAGR), from $24.34M to $2.3M.
- What does change in fair value of contingent consideration mean?
- This represents the non-cash adjustment to the fair value of liabilities associated with acquisition-related earn-outs or contingent payments. Fluctuations in this value reflect changes in the estimated probability or timing of achieving specific performance milestones post-acquisition. It is a critical indicator of potential future cash outflows related to inorganic growth strategies.